A guide to the collection of T-cells by apheresis for ATMP manufacturing-recommendations of the GoCART coalition apheresis working group.

Autor: Worel N; Department for Transfusion Medicine and Cell Therapy, Medical University of Vienna, Vienna, Austria. nina.worel@meduniwien.ac.at., Holbro A; Regional Blood Transfusion Service, Swiss Red Cross, Basel, Switzerland.; Division of Hematology, University Hospital Basel and University Basel, Basel, Switzerland.; Innovation Focus Cell Therapies, University Hospital Basel, Basel, Switzerland., Vrielink H; Department for Transfusion Medicine, Sanquin Blood Supply, Amsterdam, The Netherlands., Ootjers C; Department of Hematology, Leiden University Medical Centre, Leiden, The Netherlands., Le Poole K; Department for Transfusion Medicine, Sanquin Blood Supply, Amsterdam, The Netherlands., Beer-Wekking I; Department of Hematology, Leiden University Medical Centre, Leiden, The Netherlands., Rintala T; EBMT Executive Office, Barcelona, Spain., Lozano M; Apheresis and Cellular Therapy Unit, Department of Hemotherapy and Hemostasis, University Clinic Hospital, IDIBAPS, University of Barcelona, Barcelona, Spain., Bonig H; Institute for Transfusion Medicine and Immunohematology, Goethe University, Frankfurt a.M., Germany.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.
Jazyk: angličtina
Zdroj: Bone marrow transplantation [Bone Marrow Transplant] 2023 Jul; Vol. 58 (7), pp. 742-748. Date of Electronic Publication: 2023 Apr 06.
DOI: 10.1038/s41409-023-01957-x
Abstrakt: Autologous chimeric antigen receptor-modified T-cells (CAR-T) provide meaningful benefit for otherwise refractory malignancies. As clinical indications for CAR-T cells are expanding, hospitals hitherto not active in the field of immune effector cell therapy will need to build capacity and expertise. The GoCART Coalition seeks to disseminate knowledge and skills to facilitate the introduction of CAR-T cells and to standardize management and documentation of CAR-T cell recipients, in order to optimize outcomes and to be able to benchmark clinical results against other centers. Apheresis generates the starting material for CAR-T cell manufacturing. This guide provides some initial suggestions for patient's apheresis readiness and performance to collect starting material and should thus facilitate the implementation of a CAR-T-starting material apheresis facility. It cannot replace, of course, the extensive training needed to perform qualitative apheresis collections in compliance with national and international regulations and assess their cellular composition and biological safety.
(© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: